Non-alcoholic fatty liver disease is characterised by a reduced polyunsaturated fatty acid transport via free fatty acids and high-density lipoproteins (HDL).


Journal

Molecular metabolism
ISSN: 2212-8778
Titre abrégé: Mol Metab
Pays: Germany
ID NLM: 101605730

Informations de publication

Date de publication:
07 2023
Historique:
received: 22 01 2023
revised: 25 03 2023
accepted: 13 04 2023
medline: 27 6 2023
pubmed: 22 4 2023
entrez: 21 04 2023
Statut: ppublish

Résumé

Non-alcoholic fatty liver disease (NAFLD) develops due to impaired hepatic lipid fluxes and is a risk factor for chronic liver disease and atherosclerosis. Lipidomic studies consistently reported characteristic hepatic/VLDL "lipid signatures" in NAFLD; whole plasma traits are more debated. Surprisingly, the HDL lipid composition by mass spectrometry has not been characterised across the NAFLD spectrum, despite HDL being a possible source of hepatic lipids delivered from peripheral tissues alongside free fatty acids (FFA). This study characterises the HDL lipidomic signature in NAFLD, and its correlation with metabolic and liver disease markers. We used liquid chromatography-mass spectrometry to determine the whole serum and HDL lipidomic profile in 89 biopsy-proven NAFLD patients and 20 sex and age-matched controls. In the whole serum of NAFLD versus controls, we report a depletion in polyunsaturated (PUFA) phospholipids (PL) and FFA; with PUFA PL being also lower in HDL, and negatively correlated with BMI, insulin resistance, triglycerides, and hepatocyte ballooning. In the HDL of the NAFLD group we also describe higher saturated ceramides, which positively correlate with insulin resistance and transaminases. NAFLD features lower serum lipid species containing polyunsaturated fatty acids; the most affected lipid fractions are FFA and (HDL) phospholipids; our data suggest a possible defect in the transfer of PUFA from peripheral tissues to the liver in NAFLD. Mechanistic studies are required to explore the biological implications of our findings addressing if HDL composition can influence liver metabolism and damage, thus contributing to NAFLD pathophysiology.

Sections du résumé

BACKGROUND AND OBJECTIVES
Non-alcoholic fatty liver disease (NAFLD) develops due to impaired hepatic lipid fluxes and is a risk factor for chronic liver disease and atherosclerosis. Lipidomic studies consistently reported characteristic hepatic/VLDL "lipid signatures" in NAFLD; whole plasma traits are more debated. Surprisingly, the HDL lipid composition by mass spectrometry has not been characterised across the NAFLD spectrum, despite HDL being a possible source of hepatic lipids delivered from peripheral tissues alongside free fatty acids (FFA). This study characterises the HDL lipidomic signature in NAFLD, and its correlation with metabolic and liver disease markers.
METHODS
We used liquid chromatography-mass spectrometry to determine the whole serum and HDL lipidomic profile in 89 biopsy-proven NAFLD patients and 20 sex and age-matched controls.
RESULTS
In the whole serum of NAFLD versus controls, we report a depletion in polyunsaturated (PUFA) phospholipids (PL) and FFA; with PUFA PL being also lower in HDL, and negatively correlated with BMI, insulin resistance, triglycerides, and hepatocyte ballooning. In the HDL of the NAFLD group we also describe higher saturated ceramides, which positively correlate with insulin resistance and transaminases.
CONCLUSION
NAFLD features lower serum lipid species containing polyunsaturated fatty acids; the most affected lipid fractions are FFA and (HDL) phospholipids; our data suggest a possible defect in the transfer of PUFA from peripheral tissues to the liver in NAFLD. Mechanistic studies are required to explore the biological implications of our findings addressing if HDL composition can influence liver metabolism and damage, thus contributing to NAFLD pathophysiology.

Identifiants

pubmed: 37084865
pii: S2212-8778(23)00062-5
doi: 10.1016/j.molmet.2023.101728
pmc: PMC10176260
pii:
doi:

Substances chimiques

Fatty Acids, Nonesterified 0
Lipoproteins, HDL 0
Fatty Acids, Unsaturated 0
Phospholipids 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

101728

Subventions

Organisme : Medical Research Council
ID : MC_UU_00014/2
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_PC_13030
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_UU_00014/5
Pays : United Kingdom
Organisme : British Heart Foundation
ID : FS/18/53/33863
Pays : United Kingdom
Organisme : Department of Health
ID : IS-BRC-1215-20014
Pays : United Kingdom

Informations de copyright

Copyright © 2023 The Authors. Published by Elsevier GmbH.. All rights reserved.

Auteurs

Gabriele Mocciaro (G)

University of Cambridge, Department of Biochemistry, Cambridge, CB2 1GA, United Kingdom; Roger Williams Institute of Hepatology, Foundation for Liver Research, London, SE5 9NT, United Kingdom.

Michael Allison (M)

Addenbrooke's Hospital, Cambridge Biomedical Research Centre, Department of Medicine, United Kingdom.

Benjamin Jenkins (B)

Wellcome Trust-MRC Institute of Metabolic Science Metabolic Research Laboratories, Cambridge, CB2 0QQ, United Kingdom.

Vian Azzu (V)

Addenbrooke's Hospital, Cambridge Biomedical Research Centre, Department of Medicine, United Kingdom; Wellcome Trust-MRC Institute of Metabolic Science Metabolic Research Laboratories, Cambridge, CB2 0QQ, United Kingdom.

Isabel Huang-Doran (I)

Addenbrooke's Hospital, Cambridge Biomedical Research Centre, Department of Medicine, United Kingdom.

Luis Vicente Herrera-Marcos (LV)

Department of Biochemistry and Molecular and Cellular Biology, Veterinary Faculty, University of Zaragoza, Zaragoza, 50013, Spain.

Zoe Hall (Z)

Biomolecular Medicine, Division of Systems Medicine, Department of Metabolism, Digestion and Reproduction, Imperial College London, London, SW7 2AZ, United Kingdom.

Antonio Murgia (A)

University of Cambridge, Department of Biochemistry, Cambridge, CB2 1GA, United Kingdom.

Davies Susan (D)

Addenbrooke's Hospital, Cambridge Biomedical Research Centre, Department of Medicine, United Kingdom.

Mattia Frontini (M)

Faculty of Health and Life Sciences, Clinical and Biomedical Sciences, University of Exeter Medical School, RILD Building, Barrack Road, Exeter, EX2 5DW, United Kingdom.

Antonio Vidal-Puig (A)

Wellcome Trust-MRC Institute of Metabolic Science Metabolic Research Laboratories, Cambridge, CB2 0QQ, United Kingdom.

Albert Koulman (A)

Wellcome Trust-MRC Institute of Metabolic Science Metabolic Research Laboratories, Cambridge, CB2 0QQ, United Kingdom. Electronic address: ak675@medschl.cam.ac.uk.

Julian L Griffin (JL)

University of Cambridge, Department of Biochemistry, Cambridge, CB2 1GA, United Kingdom; The Rowett Institute, Foresterhill Campus, University of Aberdeen, Aberdeen, AB25 2ZD, United Kingdom. Electronic address: jules.griffin@abdn.ac.uk.

Michele Vacca (M)

University of Cambridge, Department of Biochemistry, Cambridge, CB2 1GA, United Kingdom; Roger Williams Institute of Hepatology, Foundation for Liver Research, London, SE5 9NT, United Kingdom; Wellcome Trust-MRC Institute of Metabolic Science Metabolic Research Laboratories, Cambridge, CB2 0QQ, United Kingdom; Aldo Moro University of Bari, Department of Interdisciplinary Medicine, Clinica Medica "C. Frugoni", Bari, 70124, Italy. Electronic address: michele.vacca@uniba.it.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH